Amyloidosis: A changing clinical perspective

References

• Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Transact R Soc Lond B Biol Sci 2001;356:203–210.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Diagnosing primary amyloidosis. Mayo Clin Proc 2002;77:1278–1279.
   PubMed Web of Science ®Google Scholar
• Perfetti V, Colli Vignarelli M, Anesi E, Garini P, Quaglini S, Ascari E, Merlini G. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 1999;84:218–221.
   PubMed Web of Science ®Google Scholar
• Stavem P, Larsen IF, Ly B, Rorvik TO. Amyloid deposits in bone marrow aspirates in primary amyloidosis. Acta Med Scand 1980208:111–113.
   PubMed Web of Science ®Google Scholar
• Krause JR. Value of bone marrow biopsy in the diagnosis of amyloidosis. South Med J 1977;70:1072–1074.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501–1505.
   Google Scholar
• Zeidman A, Sender BZ, Yarmolovsky A, Fradin Z, Mittelman M. Severe amyloidosis with mild multiple myeloma—an unusual course. Haematologica 2000;30:55–59.
   Google Scholar
• Gillmore JD, Davies J, Iqbal A, Madhoo S, Russell NH, Hawkins PN. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 2000;100:226–228.
   Web of Science ®Google Scholar
• Skinner M, Anderson jj, Simms R, Falk R, Wang M, Libbey CA, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicines only. Am J Med 1996;100:290–298.
   PubMed Web of Science ®Google Scholar
• Kingman A, Pereira NL. Cardiac amyloidosis. J S C Med Assoc 2001;97:201–206.
   PubMedGoogle Scholar
• Sidoni A, Alberti PF, Bravi S, Bucciarelli E. Amyloid tumours in the soft tissue of the legs: Case report and review of the literature. Virchows Arch 1998;432:563–566.
   PubMed Web of Science ®Google Scholar
• Nair DR, Mehta A, Mikhailidis DP, Winder AF. Multiple myeloma with primary amyloidosis. J R Soc Med 1997;90:502.
   PubMed Web of Science ®Google Scholar
• Kutlay S, Hasan T, Keven K, Nergizoglu G, Ates K, Karatan O. Primary amyloidosis presenting with massive generalized lymphadenopathy. Leuk Lymphoma 2002;43:1501–1503.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Alunann GJ, Jalal SM, Dewald GW, Larson DR, Therneau TM, et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 1998;103:704–710.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Iwata M, Ogawa M, Nagata A, Tano M, Yokoi T. Amyloidosis secondary to bronchiectasis. Nihon Kyobu Shikkan Gakkai Zasshi 1996;34:601–604.
   PubMedGoogle Scholar
• Gatel A, Cacoub P, Piette JC. AL amyloidosis combined with acquired factor V deficiency. Ann Intern Med 1998;128: 604–605.
   Google Scholar
• Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: Colchicines alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med 1997;336:1202–1207.
   Google Scholar
• Comenzo EL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998;91:3662–3670.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549–555.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RI-I, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637–642.
   Google Scholar
• Fossa A, Muer M, Kasper C, Welt A, Seeber S, Nowrousian MR. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia 1998;12:422–426.
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Inter Med 2003;42:72–77.
   PubMed Web of Science ®Google Scholar
• van Gameren, II, Hazenberg BP, Jager PL, Smith JW, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002;9:165–174.
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemoller K, Jakob C, Langelotz C, Eucker J, Possinger K. Novel approaches to the treatment of primary amyloidosis. Expert Opin Investig Drugs 2000;9:2343–2350.
   PubMed Web of Science ®Google Scholar
• van Buren M, Hene RJ, Verdonck LF, Verzijlbergen FJ, Lokhorst HM. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995;122:508–510.
   Google Scholar
• Mariette X, Clauvel JP, Brouet JC. Intensive therapy in AL amyloidosis and light-chain deposition disease. Ann Intern Med 1995;123:553.
   Google Scholar
• Georgiades CS, Neyman EG, Fishman EK. Cross-sectional imaging of amyloidosis: An organ system-based approach. J Comput Assist Tomogr 2002;26:1035–1041.
   Google Scholar
• Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplan-tation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998;101:766–769.
   PubMed Web of Science ®Google Scholar
• Comenzo EL, Michelle D, LeBlanc M, Wally Y, Zhang Y, Kica G, et al. Mobilized CD34 ± cells selected as autografts in patients with primary light-chain amyloidosis: Rationale and application. Transfusion 1998;38:60–69.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000;26:963–969.
   PubMed Web of Science ®Google Scholar
• Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999;23:967–969.
   PubMed Web of Science ®Google Scholar
• Reich G, Held T, Siegert W, Kampf D, Dörken B, Maschmeyer G. Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2001;27:341–343.
   Google Scholar
• Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe in 1998. The Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998;21:1–7.
   Google Scholar
• Badros A, Barlogie B, Siegel E, Corder-Fox M, Zangari M, Fassas A, et al. Improved outcome of allogeneic transplan-tation in high-risk multiple myeloma patients after nonmye-loablative conditioning. J Clin Oncol 2002;20:1295–1303.
   Google Scholar
• Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood 2001;98:934–939.
   PubMed Web of Science ®Google Scholar
• Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 2000;27 (Suppl. 12):79–85.
   PubMedGoogle Scholar
• Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin Oncol 2003;30(Suppl 4):22–30.
   PubMedGoogle Scholar
• Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA. Additional radiation absorbed dose estimates for Zevalin trade mark radioimmunotherapy. Cancer Biother Radiopharm 2003;18:253–258.
   Google Scholar
• Tallman MS. Advancing the treatment of hematologic malignancies through the development of targeted interven-tions. Semin Hematol 2002;39\(Suppl 3).
   Google Scholar